Today's Low
₹ 105.00
Today's High
₹ 109.40
52 Weeks Low
₹ 45.00
52 Weeks High
₹ 77.98
Lower
₹ 106.85
Upper
₹ 118.05
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. It engages in drug discovery and development of new chemical entities (NCE) in central nervous system therapies. The company's product candidates include SUVN-502 for the treatment of Alzheimer's disease and neuropsychiatric symptoms; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist for the treatment of sleep and cognitive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist for the treatment of depressive disorders. It is also develops SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist for the treatment of cognitive disorders; SUVN-I6107 for the treatment of cognitive disorders and schizophrenia; SUVN-M8036 for the treatment of psychiatric disorders; and SUVN-D1044 for the treatment of gastrointestinal disorders. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was incorporated in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
No Data Found
No of shares Outstanding
EPS-TTM
Face Value
Book Value
Net Asset Value
ROE
ROA
ROCE
Dividend Yield
Total Debt
Sales Growth
PAT Growth
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2008 | FY 2007 | FY 2006 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 345.5 | 160.5 | 196.6 | 159.5 | 398.2 | 673.8 | 581.2 | 527.7 | 477.0 | 82.8 | 67.6 | 53.4 |
Total Non-Current Assets | 137.3 | 41.4 | 25.7 | 116.0 | 22.4 | 349.6 | 322.1 | 318.8 | 291.3 | 115.7 | 105.6 | 89.5 |
Total Assets | 482.8 | 201.9 | 222.3 | 275.5 | 420.6 | 1,023.4 | 903.3 | 846.5 | 773.1 | 198.5 | 173.2 | 143.0 |
Total Current Liabilities | 105.0 | 102.2 | 109.8 | 120.0 | 157.0 | 225.8 | 208.1 | 210.6 | 127.4 | 35.1 | 25.0 | 22.0 |
Total Non-Current Liabilities | 2.5 | 3.6 | 4.5 | 12.1 | 24.5 | 30.2 | 28.2 | 40.5 | 86.4 | 57.1 | 46.8 | 30.8 |
Shareholder's Funds | 375.3 | 96.2 | 108.0 | 143.4 | 239.1 | 767.4 | 667.0 | 595.3 | 559.3 | 106.4 | 101.5 | 90.2 |
Total Liabilities | 482.8 | 201.9 | 222.3 | 275.5 | 420.6 | 1,023.4 | 903.3 | 846.5 | 773.1 | 198.5 | 173.2 | 143.0 |
The Industry Price to BV stands at 6.03, vs the Price to BV of 7.86, which results in a Positive aspect.
The Industry Current Ratio stands at 2.31, vs the Current Ratio of 1.33, which results in a Negative aspect.
The Industry Debt to Equity Ratio stands at 0.22, vs the Debt to Equity Ratio of 0.01, which results in a Positive aspect.
The Industry Quick Ratio stands at 1.60, vs the Quick Ratio of 1.33, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Income | 13.5 | 11.8 | 13.5 | 14.4 | 285.7 | 625.3 | 543.5 | 499.5 | 520.9 | 117.3 | 111.9 | 88.1 | 63.6 | 51.2 |
Total Expenditure | 139.2 | 134.1 | 93.4 | 130.1 | 296.7 | 423.6 | 414.5 | 398.2 | 361.4 | 104.6 | 95.6 | 77.3 | 55.1 | 40.9 |
Operating Profit(Excl OI) | -117.2 | -120.7 | -72.2 | -101.7 | 16.3 | 224.9 | 150.2 | 121.0 | 168.0 | 15.9 | 17.8 | 11.6 | 10.1 | 11.1 |
Add: Other Income | 8.5 | 1.6 | 7.8 | 14.0 | 27.3 | 23.3 | 21.1 | 19.6 | 8.6 | 3.2 | 1.5 | 0.8 | 1.5 | 0.8 |
Operating Profit | -117.2 | -120.7 | -72.2 | -101.7 | 16.3 | 224.9 | 150.2 | 121.0 | 168.0 | 15.9 | 17.8 | 11.6 | 10.1 | 11.1 |
Less: Interest | 0.5 | 0.7 | 0.9 | 0.6 | 1.9 | 4.6 | 5.7 | 5.9 | 4.7 | 5.1 | 3.0 | 1.7 | 0.8 | 0.8 |
PBDT | -117.7 | -121.3 | -73.1 | -102.2 | 14.4 | 220.3 | 144.5 | 115.1 | 163.3 | 10.8 | 14.8 | 10.0 | 9.2 | 10.3 |
Less: Depreciation Amortization | 6.5 | 4.4 | 4.4 | 4.2 | 14.2 | 24.8 | 21.4 | 17.5 | 11.8 | 4.4 | 4.0 | 3.5 | 3.2 | 2.0 |
PBT & Exceptional Items | -124.3 | -125.7 | -77.5 | -106.4 | 0.2 | 195.5 | 123.1 | 97.6 | 151.6 | 6.4 | 10.8 | 6.5 | 6.0 | 8.4 |
Less: Exceptional Income Expenses | 6.0 | 3.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit Before Tax | -118.3 | -122.0 | -77.5 | -106.4 | 0.2 | 195.5 | 123.1 | 97.6 | 151.6 | 6.4 | 10.8 | 6.5 | 6.0 | 8.4 |
Less: Taxation | 0.0 | 0.0 | -5.3 | -12.2 | 24.1 | 71.8 | 35.9 | 25.7 | 42.8 | -2.0 | -0.5 | 0.1 | 3.6 | 3.1 |
Profit After Tax | -118.3 | -122.0 | -72.2 | -94.2 | -23.9 | 123.7 | 87.2 | 71.9 | 108.8 | 8.4 | 11.3 | 6.4 | 2.4 | 5.3 |
Earnings Per Share | -0.1 | -0.1 | -0.1 | -0.1 | 0.0 | 0.1 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
The Industry Dividend Yield stands at 0.60, vs the Dividend Yield of 0.00, which results in a Negative aspect.
The Industry PAT Margin stands at 9.77, vs the PAT Margin of -653.62, which results in a Negative aspect.
The Industry PAT Growth stands at 32.18, vs the PAT Growth of -294.15, which results in a Negative aspect.
The Industry PE Ratio stands at 42.56, vs the PE Ratio of 0.00, which results in a Negative aspect.
Particulars | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2008 | FY 2007 | FY 2006 |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Profit Before Tax | -118.3 | -122.0 | -77.5 | -106.4 | 0.2 | 195.5 | 123.1 | 97.6 | 151.6 | 6.4 | 10.8 | 6.5 |
Tax Paid | -1.1 | -0.5 | -1.1 | -2.8 | -14.9 | -43.5 | -34.7 | -26.7 | -37.7 | -0.7 | -1.5 | -1.0 |
Adjustment | 4.7 | -1.1 | -2.7 | -8.3 | -4.9 | 10.3 | 12.9 | 11.0 | 20.8 | 11.2 | 6.5 | 6.6 |
Changes In Working Capital | -118.3 | -122.0 | -77.5 | -106.4 | 0.2 | 195.5 | 123.1 | 97.6 | 151.6 | 6.4 | 10.8 | 6.5 |
Cash Flow after changes in Working Capital | -102.0 | -127.0 | -94.9 | -131.8 | -37.7 | 113.5 | 143.9 | 94.2 | 180.6 | 4.6 | 17.8 | 6.5 |
Cash Flow from Operating Activities | -103.1 | -127.5 | -96.0 | -134.6 | -52.6 | 69.9 | 109.2 | 67.5 | 142.9 | 3.9 | 16.2 | 5.5 |
Cash Flow from Investing Activities | -260.6 | -22.2 | 55.8 | 146.2 | 37.1 | -0.6 | -310.6 | -38.6 | -110.4 | -16.2 | -20.5 | -9.4 |
Cash Flow from Financing Activities | 395.5 | 145.7 | 34.9 | 2.8 | 4.5 | -52.1 | -30.4 | -68.1 | 179.1 | 5.5 | 12.6 | 2.7 |
Net Cash Inflow / Outflow | 31.7 | -4.1 | -5.3 | 14.4 | -10.9 | 17.3 | -231.9 | -39.2 | 211.6 | -6.7 | 8.4 | -1.2 |
Opening Cash & Cash Equivalents | 5.3 | 9.3 | 14.7 | 0.2 | 17.9 | 8.7 | 240.5 | 279.7 | 67.8 | 9.8 | 1.4 | 2.6 |
Closing Cash & Cash Equivalent | 37.0 | 5.3 | 9.3 | 14.7 | 0.2 | 25.9 | 8.7 | 240.5 | 279.4 | 3.0 | 9.8 | 1.4 |
The Industry PFCF Ratio stands at 25.12, vs the PFCF Ratio of -2.29, which results in a Negative aspect.
The Industry PCF RATIO stands at 24.29, vs the PCF RATIO of -1.87, which results in a Negative aspect.
Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 | Mar 2020 | Dec 2019 | Sep 2019 | Jun 2019 | Mar 2019 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Sales | 24.5 | 30.6 | 38.0 | 26.1 | 30.0 | 43.9 | 35.4 | 42.2 | 44.3 | 11.8 | 20.1 | 15.6 | 15.1 | 89.8 | 14.3 | 86.6 | 27.7 | 2,743.2 | 1,989.9 | 2,533.0 |
Total Income | 85.2 | 82.0 | 94.4 | 82.1 | 52.1 | 45.9 | 39.8 | 43.4 | 45.7 | 16.9 | 65.6 | 28.8 | 31.4 | 112.6 | 39.6 | 116.6 | 86.3 | 2,799.0 | 2,019.9 | 2,570.5 |
Total Expenditure | 486.4 | 265.7 | 318.1 | 341.3 | 545.9 | 260.9 | 246.2 | 239.4 | 369.1 | 288.0 | 445.8 | 231.4 | 281.2 | 265.7 | 156.3 | 337.3 | 304.4 | 1,723.6 | 1,395.4 | 1,780.7 |
PBIDT (Excl OI) | -461.9 | -235.1 | -280.1 | -315.2 | -515.9 | -217.0 | -210.8 | -197.2 | -324.8 | -276.2 | -425.8 | -215.8 | -266.1 | -175.9 | -142.0 | -250.7 | -276.7 | 1,019.6 | 594.4 | 752.3 |
Other Income | 60.7 | 51.4 | 56.4 | 56.0 | 22.1 | 2.1 | 4.4 | 1.2 | 1.4 | 5.0 | 45.6 | 13.2 | 16.2 | 22.8 | 25.3 | 30.0 | 58.6 | 55.9 | 30.1 | 37.5 |
Operating Profit | -401.3 | -183.7 | -223.7 | -259.2 | -493.8 | -214.9 | -206.4 | -196.0 | -323.4 | -271.2 | -380.2 | -202.6 | -249.8 | -153.2 | -116.7 | -220.8 | -218.2 | 1,075.4 | 624.5 | 789.8 |
Interest | 0.4 | 0.4 | 0.5 | 0.5 | 0.6 | 0.7 | 1.0 | 1.0 | 1.3 | 1.5 | 1.5 | 2.4 | 1.8 | 2.6 | 2.2 | 2.3 | 1.0 | 22.9 | 16.9 | 15.8 |
Exceptional Items | 0.0 | 74.6 | 0.0 | 0.0 | 0.0 | 0.0 | 60.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
PBDT | -401.6 | -109.5 | -224.3 | -259.7 | -494.5 | -215.6 | -147.5 | -197.0 | -324.7 | -272.7 | -381.7 | -205.0 | -251.6 | -155.8 | -118.9 | -223.1 | -219.2 | 1,052.5 | 607.6 | 774.1 |
Depreciation | 16.0 | 17.3 | 16.7 | 16.7 | 16.7 | 16.2 | 15.8 | 11.0 | 12.2 | 10.3 | 10.3 | 10.7 | 11.4 | 10.8 | 10.7 | 10.5 | 8.6 | 55.9 | 55.5 | 54.6 |
Profit Before Tax | -417.7 | -126.8 | -240.9 | -276.5 | -511.2 | -231.8 | -163.3 | -208.0 | -336.9 | -283.0 | -392.1 | -215.7 | -263.0 | -166.5 | -129.6 | -233.6 | -227.7 | 996.6 | 552.1 | 719.4 |
Tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.5 | -19.1 | -10.0 | -24.7 | 22.0 | 0.4 | 363.5 | 290.0 | 340.3 |
Provisions and contingencies | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Profit After Tax | -417.7 | -126.8 | -240.9 | -276.5 | -511.2 | -231.8 | -163.3 | -208.0 | -336.9 | -283.0 | -392.1 | -216.1 | -243.9 | -156.6 | -104.9 | -255.6 | -228.1 | 633.1 | 262.1 | 379.1 |
Net Profit | -417.7 | -126.8 | -240.9 | -276.5 | -511.2 | -231.8 | -163.3 | -208.0 | -336.9 | -283.0 | -392.1 | -216.1 | -243.9 | -156.6 | -104.9 | -255.6 | -228.1 | 633.1 | 262.1 | 379.1 |
ADDITIONAL INFOS: | ||||||||||||||||||||
Equity Capital | 218.1 | 218.1 | 218.1 | 218.1 | 218.1 | 145.4 | 145.4 | 145.4 | 127.3 | 127.3 | 127.3 | 127.3 | 127.3 | 127.3 | 127.3 | 127.3 | 127.3 | 127.3 | 127.3 | 127.3 |
Reserves | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9,100.9 | 8,417.8 | 8,182.7 |
EPS | -1.9 | -0.6 | -1.1 | -1.2 | -2.9 | -1.6 | -1.1 | -1.6 | -2.7 | -2.2 | -3.1 | -1.7 | -1.9 | -1.2 | -0.8 | -2.0 | -1.8 | 5.0 | 2.1 | 3.0 |
Operating Profit Margin | -1,637.2 | -600.3 | -589.3 | -992.7 | -1,644.9 | -489.9 | -583.3 | -464.3 | -729.5 | -2,290.1 | -1,895.4 | -1,301.2 | -1,651.2 | -170.5 | -816.4 | -254.9 | -786.7 | 39.2 | 31.4 | 31.2 |
Net Profit Margin | -1,704.0 | -414.4 | -634.4 | -1,058.8 | -1,702.7 | -528.4 | -461.3 | -492.7 | -760.0 | -2,390.1 | -1,954.5 | -1,388.2 | -1,612.2 | -174.3 | -734.0 | -295.1 | -822.7 | 23.1 | 13.2 | 15.0 |
The Industry Net Sales Growth stands at 11.07, vs the Net Sales Growth of -94.95, which results in a Negative aspect.
The Industry Mcap Growth stands at 19.69, vs the Mcap Growth of -91.80, which results in a Negative aspect.
Type | Classic | Woodie | Camarilla |
---|---|---|---|
R4 | 117.15 | 123.45 | 109.18 |
R3 | 114.93 | 114.40 | 107.66 |
R2 | 112.72 | 112.45 | 107.16 |
R1 | 109.43 | 108.90 | 106.65 |
Pivot | 107.22 | 106.95 | 107.22 |
S1 | 103.93 | 103.40 | 105.65 |
S2 | 101.72 | 101.45 | 105.14 |
S3 | 98.43 | 97.90 | 104.64 |
S4 | 95.15 | 90.45 | 103.13 |
(All Values are in INR)
1 Day
1 Week
1 Month
Stoch RSI
6.91
Bullish
RSI
44.69
Neutral
ROC
-2.60
Bearish
UltimateOscillator
38.73
Neutral
Williams Indicator
-76.74
Neutral
CCI Indicator
-15.30
Neutral
MACD
-2,846.08
Bearish
Stochastic Indicator
37.66
Neutral
ATR
5.71
High Volatility
Ex-Date | Ratio | Record Date |
---|
Ex-Date | Ratio | Record Date |
---|
Announcement Date | Dividend Amount | Dividend Percentage of FV | Dividend Type |
---|
Date Of Conduct | Board Meeting Details |
---|---|
30-01-2024 | Quarterly Results |
04-11-2023 | Quarterly Results |
08-08-2023 | Quarterly Results |
09-05-2023 | Quarterly Results & Audited Results |
02-02-2023 | Quarterly Results |
10-11-2022 | Quarterly Results |
12-10-2022 | Right Issue of Equity Shares |
26-07-2022 | Quarterly Results |
24-06-2022 | Rights Issue & Inter alia, to consider matters related to raising of funds through issue of equity shares of the Company on rights basis to the existing equity shareholders of the Company in accordance with provisions of Companies Act, 2013 and SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended and other matters related/ incidental thereto including the constitution of a Committee of Board of Directors namely ?Rights Issue Committee? to implement the proposal of Rights Issue. |
07-05-2022 | Audited Results |
31-01-2022 | Quarterly Results |
25-10-2021 | Quarterly Results |
09-08-2021 | Quarterly Results |
04-05-2021 | Audited Results |